Insmed Stock Dips After HS Drug Trial Fails

Insmed Stock Declines on Trial Discontinuation

Insmed Incorporated, traded under NASDAQ:INSM, experienced a 2% decline in its stock price during after-hours trading. The drop followed the company's announcement to halt its hidradenitis suppurativa or HS program after its lead drug candidate, brensocatib, failed to achieve its objectives in a Phase 2b clinical trial.

Trial Overview and Efficacy Results

The CEDAR study, a randomized, double-blind, placebo-controlled trial, evaluated brensocatib in 214 adult patients with moderate to severe HS. The trial did not meet its primary or secondary efficacy endpoints. Results at Week 16 showed that the placebo group achieved a 57.1% reduction in total abscess and inflammatory nodule count from baseline, which was significantly better than the 45.5% reduction in the 10 mg brensocatib group and the 40.3% reduction in the 40 mg group.

Market and Company Impact

The direct market impact was a 2% decrease in INSM's share value in after-hours trading. Following the trial's failure to demonstrate efficacy, Insmed confirmed it will discontinue all development of brensocatib for the HS indication. Despite the lack of efficacy, the company reported that brensocatib was well tolerated, and no new safety signals were identified, even at the highest tested dose of 40 mg.

Summary and Outlook

The termination of the brensocatib program for HS marks a setback for this specific development pipeline. Insmed plans to present the full data from the CEDAR study at a future scientific congress. The company noted that the absence of established animal models makes clinical development in hidradenitis suppurativa particularly challenging.

FAQ

Q: Why did Insmed's stock fall?
A: The stock fell 2% after the company announced its Phase 2b trial for the drug brensocatib in treating hidradenitis suppurativa failed, leading to the discontinuation of the program.

Q: What were the key results of the Insmed trial?
A: The trial's placebo group showed a greater improvement, a 57.1% reduction in symptoms, compared to the groups receiving brensocatib, which saw reductions of 45.5% and 40.3%.

Q: What is the future of brensocatib?
A: Insmed has stopped the development of brensocatib specifically for the hidradenitis suppurativa indication due to these trial results.

Source: Investing.com